News – Page 1064 – Endpoints News

Biogen shares tumble after key exec notes a changeup to pivotal aducanumab study due to 'variability'

8 years ago

J&J wins snap approval of apalutamide, the first drug OK'd for nonmetastatic prostate cancer

8 years ago

Post-conspiracy claims, Arcturus loses another executive amid board putsch; Gates Foundation hands $6.5M to Novartis ...

8 years ago

Stock slumps for Tel Aviv's Galmed following PhIIa NAFLD flop

8 years ago

Senior Merck chemist charged with risking catastrophe after pouring cyanide into Pennsylvania stormwater drain

8 years ago

Switzerland's Ferring Pharma to build $32M discovery, development and manufacturing center at HQ

8 years ago

What does biotech think about ‘right-to-try'? It might surprise you

8 years ago

Bristol-Myers lassos the next big thing in I/O, grabs '214 rights in a record $3.6B deal with Nektar

8 years ago

Merck just dashed the last remaining hopes for its industry-leading BACE drug for Alzheimer's

8 years ago

Tetraphase’s second PhIII for its lead antibiotic fails in a repeat setback for UTIs

8 years ago

Kadmon shares jump on limited IPF data; Cellectis granted two US patents for editing T cells with CRISPR

8 years ago

AI startup BioXcel Therapeutics shoots for $69M IPO with drugs for Alzheimer's, cancer

8 years ago

$100B in NIH-funded research played an important role in all 210 new drugs approved over 7 years — study

8 years ago

Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race

8 years ago

Charles River bags a rival CRO player in $800M MPI Research buyout

8 years ago

New year, new tax rates. How did the world’s biggest drugmakers fare?

8 years ago

Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff

8 years ago

On a roll, Vertex grabs FDA OK for CF double shot Symdeko — prices at $292,000

8 years ago

Taking on a big challenge, ex-Celgene CEO Bob Hugin readies a run for the Senate

8 years ago

BD exec Goater replaces Biniszkiewicz as chief at Surface Oncology; Ardelyx bids farewell to CSO Caldwell

8 years ago

What's the trouble with pain? Analysis shows scarce investments, high failure rate for new drugs

8 years ago

Ex-FDA commish Califf joins Cytokinetics’ board just months after big ALS flop

8 years ago

Once rejected, FDA now rolls out a short red carpet for Amicus’ migalastat

8 years ago

Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea

8 years ago

First page Previous page 1061 1062 106310641065 1066 1067 Next page Last page